Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023
11 déc. 2023 19h30 HE
|
Gracell Biotechnologies Inc.
Minimal residual disease negativity (MRD-) observed in all treated patients in the ongoing study, with 95% (21/22) achieving stringent complete response (sCR) through a median follow-up of 18.8 months...
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting
11 déc. 2023 15h00 HE
|
Wugen
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at ASH 2023
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
27 nov. 2023 08h00 HE
|
Gracell Biotechnologies Inc.
Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and wider depletion of disease-causing antibody secreting cells...
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
17 nov. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...
L’Assemblée Générale Extraordinaire de Cellectis se tiendra le 22 décembre 2023
17 nov. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, 17 nov. 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d’édition de génome...
Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit
16 nov. 2023 08h00 HE
|
Gracell Biotechnologies Inc.
Presentation to focus on application of next-generation CAR-T cell therapy technologies for treatment of autoimmune disease Gracell to highlight translational research supporting CD19/BCMA...
CARGO Therapeutics Announces Pricing of Initial Public Offering
09 nov. 2023 20h07 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announce Pricing of IPO
Celyad Oncology reports third quarter 2023 financial results and recent business highlights
09 nov. 2023 01h00 HE
|
Celyad Oncology SA
Publication of data detailing the development of our microRNA (miRNA)-based multiplex shRNA approach, which allows to down-regulate several genes simultaneously, in Molecular Therapy – Nucleic...
Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program
08 nov. 2023 08h30 HE
|
Gracell Biotechnologies Inc.
Third annual BioTech Breakthrough Award recognizes excellence in life science and biotechnology solutions, services and companies GC012F, a FasTCAR-enabled autologous CAR-T cell therapy, is...
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
02 nov. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...